ProCE Banner Activity

Improving Outcomes in Major Depression: Focus on Individualizing Treatment

Slideset Download

Slides from the major depressive disorder presentation at the 2022 Psychopharmacology Update conference.

Released: December 01, 2022

Expiration: November 30, 2023

Share

Faculty

Greg W. Mattingly

Greg W. Mattingly, MD

Associate Clinical Professor
Department of Psychiatry
Washington University School of Medicine
President
St. Charles Psychiatry Associates
St. Louis, Missouri

Supporters

Supported by an educational grant from

AbbVie Inc.

Faculty Disclosure

Primary Author

Greg W. Mattingly, MD

Associate Clinical Professor
Department of Psychiatry
Washington University School of Medicine
President
St. Charles Psychiatry Associates
St. Louis, Missouri

Greg W. Mattingly, MD: consultant/advisor/speaker: AbbVie, Acadia, Alkermes, Axsome, Corium, Eisai, Ironshore, Intracellular, Janssen, Lundbeck, Neos, Neurocrine, Noven, Otsuka, Redax, Roche, Rhodes, Sage, Sirona, Sunovion, Supernus, Takeda, Teva, Trispharma; researcher: AbbVie, Acadia, Alkermes, Akili, Axsome, Boehringer Ingelheim, Emalex, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, NLS-1 Pharma AG, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, Teva.